Menu
Expand your knowledge.
Two NASH drugs on the horizon for market approval within 12 months: Are you ready?
Listen to expert panel Dr. Stephen Harrison, Dr. Maru/Mary Rinella and Dr. Mazen Noureddin as they discuss the practical implications of a NASH drug approval. Moderated by Michael Betel, President and Founder of the Fatty Liver Alliance, an organization that provides awareness, education, research, and advocacy around fatty liver disease. www.fattyliver.ca
Key points covered:
Dr. Harrison is currently the Chairman of both Summit and Pinnacle Clinical Research LLC located in San Antonio, Texas. He is a Visiting Professor of Hepatology at the Radcliffe Department of Medicine at the University of Oxford. He earned his medical degree from the University of Mississippi School of Medicine and completed his Internal Medicine residency and Gastroenterology fellowship at Brooke Army Medical Center and a fourth-year advanced liver disease fellowship at Saint Louis University. He is board certified in both Internal Medicine and Gastroenterology. Dr. Harrison is internationally known for his studies in non alcoholic fatty liver disease with more than 250 peer-reviewed publications and an H-Index of 81. He is a past Associate Editor for both Hepatology and Alimentary Pharmacology and Therapeutics, and a peer-reviewer for over 20 medical journals.
Dr. Rinella is a Professor of Medicine at the University of Chicago Pritzker School of Medicine where she is the Director of the Metabolic and Fatty Liver Program. Currently, her clinical research focus is in the area of non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) both before and after liver transplantation. She is the lead author of the 2022 AASLD NAFLD Practice Guidance. She has held several national leadership roles in the field of NAFLD and is currently Chair of the AASLD NASH Task Force. As Chair of the NASH Task Force, she is charged with fostering research collaboration and advancing best practices through collaboration with other medical societies, federal agencies, and patient advocacy organizations to improve outcomes in patients with NASH. She is currently co-directing the NAFLD nomenclature process.
Dr. Noureddin was the founding director of the Fatty Liver Program at Cedars Sinai Medical Center. He recently relocated to Texas from California to establish the state-of-the-art Houston Research Institute specializing in fatty liver disease, as well as to join the Lynda K. and David M. Underwood Center for Digestive Disorders and the Sherrie and Alan Conover Center for Liver Disease and Transplantation at the Houston Methodist Hospital. Dr. Noureddin is internationally known for his research in the areas of NAFLD/NASH and NASH-related cirrhosis and is an expert in non-invasive testing and biomarkers. He has conducted more than forty clinical studies for novel treatments for NASH and has served on numerous consensus panels by multiple international societies including the AASLD and EASL, as well as industry advisory boards. He is currently the Vice Chair of the AASLD NASH special interest group and serves on the editorial board for major GI journals including Gastroenterology, Hepatology, and Clinical Gastroenterology and Hepatology.
Michael Betel is the President and Founder of the Fatty Liver Alliance, a charity focused on the early detection, prevention, and treatment of NAFLD and NASH. He has been a leader in the area of liver disease, in both commercial and not-for-profit organizations for over 25 years, as a Director at Hoffmann-La Roche and Canadian Blood Services, and as a sales and marketing leader at Schering-Plough. He was a Director on the board of a national liver-focused health charity for 9 years. He is currently the Chair of the Global Liver Institute’s Liver Action Network, which includes 12 community liver advocacy organizations.
